Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	16.36B
Revenue (ttm)	2.82B
Net Income (ttm)	142.16M
Shares Out	1.60B
EPS (ttm)	0.09
PE Ratio	115.07
Forward PE	40.92
Dividend	0.01 (0.10%)
Ex-Dividend Date	May 30, 2024

Volume	16,382,038
Average Volume	25,903,361
Open	10.30
Previous Close	10.15
Day's Range	10.07 - 10.30
52-Week Range	9.70 - 18.98
Beta	0.91
RSI	34.19
Earnings Date	Apr 26, 2025

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.